M.H.M.A. Bosman

Bosman, M., Vork, L., Jonkers, D., Snijkers, J., Topan, R., Aziz, Q., Midenfjord, I., Simren, M., Masclee, A., Keszthelyi, D., & ESM study group (2025). Results From a Psychometric Validation Study: Patients with Irritable Bowel Syndrome Report Higher Symptom Burden Using End-of-Day Vs Real-Time Assessment. The American Journal of Gastroenterology, 120(5), 1098-1107. https://doi.org/10.14309/ajg.0000000000003091

Bosman, M. H. M. A., Weerts, Z. Z. R. M., Snijkers, J. T. W., Vork, L., Mujagic, Z., Masclee, A. A. M., Jonkers, D. M. A. E., & Keszthelyi, D. (2023). The Socioeconomic Impact of Irritable Bowel Syndrome: An Analysis of Direct and Indirect Health Care Costs. Clinical gastroenterology and hepatology, 21(10), 2660-2669. https://doi.org/10.1016/j.cgh.2023.01.017

Bosman, M., Smeets, F., Elsenbruch, S., Tack, J., Simren, M., Talley, N., Winkens, B., Masclee, A., & Keszthelyi, D. (2023). Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis. Neurogastroenterology and Motility, 35(2), Article e14474. https://doi.org/10.1111/nmo.14474

Bosman, M., Elsenbruch, S., Corsetti, M., Tack, J., Simren, M., Winkens, B., Boumans, T., Masclee, A., & Keszthelyi, D. (2021). The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 6(6), 459-473. https://doi.org/10.1016/S2468-1253(21)00023-6

Bosman, M. H. M. A., & Keszthelyi, D. (2020). Letter: placebo run-in for IBS clinical trials-is it useful? Alimentary Pharmacology & Therapeutics, 52(7), 1237-1238. https://doi.org/10.1111/apt.16027